{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:54:34Z","timestamp":1765828474323,"version":"3.46.0"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>It is essential to evaluate both the patient's prior conditions and the severity of the current clinical presentation when deciding on BTZ toxicity management. It seems prudent to consider the permanent discontinuation of the drug in patients who have experienced at least grade 3 intestinal neuropathy and have structural abnormalities or other risk factors for intestinal perforation.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    NCT03710603\n                  <\/jats:p>","DOI":"10.1002\/ccr3.70340","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T06:26:49Z","timestamp":1743488809000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intestinal Perforation Secondary to Bortezomib\u2010Induced Autonomic Neuropathy"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0140-044X","authenticated-orcid":false,"given":"Jose Antonio","family":"S\u00e1nchez Salas","sequence":"first","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Moreno Belmonte","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Poveda Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Ruiz Ruiz","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Soler Espejo","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2549","authenticated-orcid":false,"given":"Valentin","family":"Cabanas Perianes","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Garc\u00eda Hernandez","sequence":"additional","affiliation":[{"name":"Department of Hematology Virgen de la Arrixaca University Hospital  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8\u20106\u2010508"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020888"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112068"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010014\u20101316\u20105"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010816.pub2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.52768\/2766\u20107820\/2333"},{"key":"e_1_2_9_8_1","unstructured":"European Myeloma Network BV \u201cA Phase 3 Study Comparing Daratumumab Velcade (Bortezomib) Lenalidomide and Dexamethasone (D\u2010VRd) vs. Velcade Lenalidomide and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High\u2010Dose Therapy \u201dClinicalTrials.gov Report No.: NCT03710603 https:\/\/clinicaltrials.gov\/study\/NCT03710603."},{"key":"e_1_2_9_9_1","unstructured":"U.S. Department of Health and Human Services National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201d(2017) https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"volume-title":"Velcade: EPAR \u2013 Product Information","year":"2009","author":"European Medicines Agency","key":"e_1_2_9_10_1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13017\u2010018\u20100192\u20103"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102016\u2010217000"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.051"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32811ebffe"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405087"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010015\u20100337\u20106"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000930"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.70340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:54:17Z","timestamp":1764255257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.70340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/ccr3.70340"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.70340","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70340"}}